Alpha DNA Investment Management LLC Sells 4,998 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Alpha DNA Investment Management LLC reduced its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 48.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,238 shares of the company's stock after selling 4,998 shares during the quarter. Alpha DNA Investment Management LLC's holdings in GeneDx were worth $403,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MCF Advisors LLC raised its holdings in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after buying an additional 182 shares during the last quarter. Sterling Capital Management LLC raised its holdings in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after acquiring an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new position in GeneDx in the 4th quarter valued at approximately $28,000. Rhumbline Advisers boosted its stake in GeneDx by 5.5% during the 4th quarter. Rhumbline Advisers now owns 19,750 shares of the company's stock valued at $1,518,000 after purchasing an additional 1,021 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of GeneDx by 10.6% in the 4th quarter. Principal Financial Group Inc. now owns 15,751 shares of the company's stock worth $1,211,000 after purchasing an additional 1,511 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Stock Performance

GeneDx stock traded up $0.93 during mid-day trading on Thursday, reaching $106.62. 404,137 shares of the stock traded hands, compared to its average volume of 691,460. GeneDx Holdings Corp. has a 12-month low of $10.70 and a 12-month high of $115.60. The business's 50-day moving average is $95.15 and its 200-day moving average is $80.85. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market capitalization of $2.99 billion, a PE ratio of -54.35 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84. Following the sale, the chief financial officer now directly owns 5,446 shares of the company's stock, valued at $515,845.12. This trade represents a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Katherine Stueland sold 46,594 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total value of $4,175,754.28. Following the completion of the transaction, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at approximately $154,146.40. This trade represents a 96.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 138,780 shares of company stock worth $12,907,437 in the last three months. Corporate insiders own 27.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on WGS. The Goldman Sachs Group upped their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.